Propanc Biopharma Stock Forward View - 4 Period Moving Average
| PPCB Stock | USD 0.14 -0.03 -17.65% |
Predicting Propanc Biopharma's future price is a multi-variable problem that combines fundamental signals, technical structure, and market sentiment. This module focuses specifically on the hype and news dimension of that forecast.
At present, the 14-period RSI for Propanc Biopharma registers 24, placing the security in oversold territory. Values below 30 typically indicate extended downward momentum relative to recent price action.Momentum
Sell Stretched
Oversold | Overbought |
Wall Street Target Price 1.52 |
This section relates Propanc Biopharma Common headline activity to recent price behavior and peer context.
The 4 Period Moving Average forecasted value of Propanc Biopharma Common on the next trading day is expected to be 0.15 with a mean absolute deviation of 0.03 and the sum of the absolute errors of 1.97.Propanc Biopharma after-hype prediction price | $ 0.14 |
Hype signals are presented as complementary context to forecasting, technicals, analyst estimates, earnings, and momentum.
Use Historical Fundamental Analysis of Propanc Biopharma to cross-verify projections for Propanc Biopharma. The historical view provides additional context.Propanc Biopharma Additional Predictive Modules
Most predictive techniques to examine Propanc price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Propanc using various technical indicators. When you analyze Propanc charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Propanc Biopharma 4 Period Moving Average Price Forecast For the 13th of March 2026
Given 90 days horizon, the 4 Period Moving Average forecasted value of Propanc Biopharma Common on the next trading day is expected to be 0.15 with a mean absolute deviation of 0.03 , mean absolute percentage error of 0.0019 , and the sum of the absolute errors of 1.97 .Please note that although there have been many attempts to predict Propanc Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Propanc Biopharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Propanc Biopharma Stock Forecast Pattern
| Backtest Propanc Biopharma | Propanc Biopharma Price Prediction | Research Analysis |
Propanc Biopharma Forecasted Value
This next-day forecast for Propanc Biopharma Common uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the 4 Period Moving Average forecasting method's relative quality and the estimations of the prediction error of Propanc Biopharma stock data series using in forecasting. Note that when a statistical model is used to represent Propanc Biopharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 106.336 |
| Bias | Arithmetic mean of the errors | 0.0264 |
| MAD | Mean absolute deviation | 0.0339 |
| MAPE | Mean absolute percentage error | 0.1089 |
| SAE | Sum of the absolute errors | 1.9675 |
The concept of mean reversion suggests that Propanc Biopharma's price will eventually return toward its long-run average. High prices may deter value investors, while unusually low prices often attract buyers who anticipate a recovery.
Propanc Biopharma After-Hype Price Density Analysis
The price distribution graph for Propanc Biopharma visualizes the statistical uncertainty around our prediction model's output. Investors should interpret the full distribution of Propanc Biopharma's outcomes, not just the central tendency, when making decisions.
Next price density |
| Expected price to next headline |
Propanc Biopharma Estimiated After-Hype Price Volatility
The downside and upside margins for Propanc Biopharma after major news events are estimated from historical precedent. Propanc Biopharma's after-hype downside and upside margins for the prediction period are 0.01 and 8.46, respectively. This approach captures the empirical distribution of Propanc Biopharma's short-term price reactions without assuming any particular model of future behavior.
Current Value
The after-hype framework applied to Propanc Biopharma Common assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Propanc Biopharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Propanc Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Propanc Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Propanc Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.49 | 8.39 | 0.02 | 0.01 | 6 Events | 1 Events | In 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.14 | 0.14 | 0.00 |
|
Propanc Biopharma Hype Timeline
Propanc Biopharma Common is at this time traded for 0.14. The company has historical hype elasticity of -0.02, and average elasticity to hype of competition of -0.01. Propanc is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at -2.49%. %. The volatility of related hype on Propanc Biopharma is about 139833.33%, with the expected price after the next announcement by competition of 0.13. About 53.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Propanc Biopharma Common recorded earning per share (EPS) of 52.11. The company last dividend was issued on the 19th of November 2020. The firm completed a 1:2 stock split on 29th of January 2025. Given the investment horizon of 90 days the next forecasted press release will be in 6 days. Use Historical Fundamental Analysis of Propanc Biopharma to cross-verify projections for Propanc Biopharma. The historical view provides additional context.Propanc Biopharma Related Hype Analysis
The relationship between Propanc Biopharma and its sector peers means that news affecting one company often reverberates across Propanc Biopharma's competitive landscape. Tracking peer hype helps investors anticipate Propanc Biopharma's likely short-term price behavior.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| QPTFF | Quest PharmaTech | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| GLABF | Gemina Laboratories | 0.00 | 0 per month | 0.00 | -0.04 | 0.00 | -22.00 | 144.07 | |
| TELIF | Telescope Innovations Corp | 0.00 | 0 per month | 5.36 | 0.02 | 12.50 | -10.53 | 69.65 | |
| PRVCF | PreveCeutical Medical | 0.00 | 0 per month | 15.16 | 0.11 | 35.00 | -24.73 | 476.32 | |
| SYGGF | Synairgen plc | -0.02 | 2 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| IMUC | ImmunoCellular Therapeutics | 0.00 | 0 per month | 19.13 | 0.1 | 63.64 | -42.11 | 237.25 | |
| CLCS | Cell Source | -0.02 | 4 per month | 4.31 | 0.24 | 15.00 | -9.09 | 33.08 | |
| ZHCLF | Zenith Capital Corp | 0.00 | 0 per month | 75.31 | 0.17 | 160.00 | -58.33 | 33,292 | |
| HOOK | Hookipa Pharma | -0.02 | 2 per month | 1.11 | 0.18 | 3.96 | -2.25 | 10.16 | |
| SRBCF | Sirona Biochem Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Forecasting Options for Propanc Biopharma
Whether a novice or experienced investor, anyone considering Propanc needs to understand the dynamics of Propanc Biopharma's price movement. Price charts for Propanc Stock contain a significant amount of noise that can distort investment decisions.Propanc Biopharma Related Equities
The following equities are related to Propanc Biopharma within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Propanc Biopharma against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Propanc Biopharma Market Strength Events
Analyzing market strength indicators for Propanc Biopharma enables investors to understand how the stock performs relative to overall market momentum. These indicators are valuable tools for identifying when to enter or exit positions in Propanc Biopharma Common.
Propanc Biopharma Risk Indicators
Identifying and analyzing Propanc Biopharma's key risk indicators is a foundational step in projecting how its price may evolve. This process helps investors quantify the risk associated with Propanc Biopharma's and decide how to manage it.
| Mean Deviation | 5.17 | |||
| Standard Deviation | 8.02 | |||
| Variance | 64.32 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Propanc Biopharma
Coverage intensity for Propanc Biopharma Common matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Other Macroaxis Stories
Story coverage on Macroaxis is built for readers who approach markets from different levels of experience but share the same need for disciplined investment context. Used well, these stories become part of a broader workflow built around idea generation, validation, and risk-adjusted portfolio design.
Story Categories
Currently Trending Categories
Propanc Biopharma Short Properties
Short sentiment tied to Propanc Biopharma Common matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 4 M | |
| Cash And Short Term Investments | 12.1 K |
More Resources for Propanc Stock Analysis
A structured review of Propanc Biopharma Common often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame Propanc Biopharma Common Stock in context:Use Historical Fundamental Analysis of Propanc Biopharma to cross-verify projections for Propanc Biopharma. The historical view provides additional context. Analysis related to Propanc Biopharma should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
The market value of Propanc Biopharma Common is measured differently than book value, which reflects Propanc accounting equity. Propanc Biopharma's market capitalization is 2.17 M. A P/B ratio of 0.21 suggests Propanc Biopharma trades near or below book value. Enterprise value stands at 3.26 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Propanc Biopharma's intrinsic value and market price are different measures derived from different inputs. For Propanc Biopharma, key inputs include a P/B ratio of 0.21, and ROE of -18.12%. Trading price represents the transaction level agreed by market participants.